Epygen Biotech Pvt Ltd

Epygen Biotech Pvt Ltd (EBPL) would be launching its entry Biosimilar molecule Recombinant Streptokinase (rSK) in 2018, under License and Technology transfer by CSIR-IMTECH. This well-proven technology has been improvised for enhanced product performance and patient safety profile. Epygen’s oncology product pipeline consists Pegfilgrastim and Bevacizumab, jointly posting more than US$ 10 billion Global opportunity. It’s expertise on E.coli based expression of recombinant protein, coupled with innovative fermentation, protein refolding and separation techniques are utilized for high expression and purification of these molecules, making them affordable for patients in the region. The technology incubation center is based in Navi Mumbai and the plant is based in the heart of pharmaceutical production zone in Patalganga, near Mumbai.